ATRIUM HEALTH UNION
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $36.8M
- Transactions
- 2,887
- Companies
- 40
- Average per transaction
- $12,736
Who reported the payments
| Janssen Research & Development, LLC | $8,738,057 |
| Merck | $3,973,548 |
| Bristol Myers Squibb | $2,712,287 |
| Pfizer | $2,588,654 |
| CSL Behring | $2,517,296 |
| Gilead | $2,086,352 |
| Seagen Inc. | $1,725,772 |
| AstraZeneca | $1,655,713 |
| E.r. Squibb & Sons, L.L.C. | $1,534,540 |
| Intercept Pharmaceuticals, Inc. | $1,370,472 |
| AbbVie | $1,317,619 |
| Takeda Pharmaceuticals U.S.A., Inc. | $916,451 |
| USWM, LLC | $689,924 |
| Edwards Lifesciences | $515,728 |
| Eli Lilly | $446,962 |
| Tanabe Pharma America, Inc. | $435,493 |
| Medical Device Business Services, Inc. | $379,419 |
| Lilly USA, LLC | $347,143 |
| Regeneron | $272,904 |
| Global Blood Therapeutics, Inc. | $168,148 |
| Biotronik Inc. | $158,852 |
| Pharmacyclics LLC, An Abbvie Company | $143,912 |
| Intercept Pharma Europe Ltd. | $143,186 |
| Jazz Pharmaceuticals Inc. | $139,235 |
| Genmab U.S., Inc. | $131,606 |
| Mitsubishi Tanabe Pharma Development America, Inc. | $96,667 |
| Stryker | $82,079 |
| Epizyme, Inc. | $79,587 |
| Penumbra, Inc. | $76,106 |
| Johnson & Johnson | $74,210 |
| Bayer | $71,941 |
| Ethicon Endo-surgery Inc. | $66,735 |
| Astrazeneca UK Limited | $65,366 |
| Karyopharm Therapeutics Inc. | $63,659 |
| Incyte Corporation | $62,968 |
| Janssen Scientific Affairs, LLC | $58,809 |
| Boston Scientific | $57,339 |
| Artivion, Inc. | $48,839 |
| Sanofi | $48,691 |
| Hoffmann-la Roche Limited | $46,967 |